Navigation Links
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture
Date:6/3/2008

tacarpophalangeal (MP) or proximal interphalangeal (PIP) joints to < / = 5 degrees of normal. In CORD I, MP and PIP patients were stratified in a 2:1 ratio.

All patients receiving XIAFLEX in the double-blind portion of the study will be monitored for a minimum of 12 months following initial dosing. After finishing the double-blind portion, XIAFLEX and placebo patients are also eligible to receive additional XIAFLEX injections for either unsuccessfully treated joints or additional untreated joints during an open-label, extended treatment period. This open-label phase was designed to provide further data for the long-term safety and efficacy of XIAFLEX injections in the treatment of Dupuytren's contracture.

About CORD II

This Australian study is a supportive double-blind, randomized, placebo-controlled study with an open-label extension that enrolled 66 patients in five sites. The design of this study is similar to that of the pivotal U.S. phase III trial (CORD I) and its open-label extension. The primary endpoint was the reduction of contracture angle in MP or PIP joints to < / = 5 degrees of normal. In CORD II, MP and PIP patients were stratified in a 1:1 ratio.

After finishing this double-blind portion, patients from both XIAFLEX and placebo groups will be permitted to receive additional XIAFLEX injections for either unsuccessfully treated joints or additional untreated joints during an open-label, extended treatment period. This open-label phase was designed to provide further data for the long-term safety and efficacy of XIAFLEX injections in the treatment of Dupuytren's contracture.

About JOINT I and II

In addition to the open-label extensions of CORD I and II, the Company is concurrently conducting two phase III open-label studies in approximately 600 patients. These studies will provide additional safety and efficacy data and will contribute to the safety database that is required for the BLA.

About Auxilium '/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
3. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
4. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
5. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
6. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
7. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
8. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
9. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
10. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... positive results from its pivotal field study of ... pain in dogs with osteoarthritis.  In the study, ... scores that were statistically significant compared to placebo ...
(Date:12/19/2014)... separating membrane market has witnessed robust development with ... albeit as a later starter. In 2012, the size of ... RMB12 billion, with the proportion worldwide soaring to 16.3%. It ... market will continue its growth rate by around 20% in ... jump to roughly RMB25 billion. An integrated membrane ...
(Date:12/17/2014)... December 17, 2014 Los beneficios ... un alto nivel de gasto en investigación y desarrollo ... (finalizado el 30 de septiembre de 2014) ZEISS aumentó ... millones de euros (año anterior: 4.190 millones de euros) ... Las ganancias (EBIT) crecieron un 14 por ciento, a ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3ZEISS confirma su posición en un entorno difícil 2
... ALTO, Calif., Oct. 1 Telik, Inc. (Nasdaq: TELK ... a Phase 1-2a multicenter, dose-ranging study of TELCYTA in combination ... nonsmall cell lung cancer (NSCLC) in a leading peer reviewed ... Vol. 4, No. 10. Data on this study were ...
... , MOUNTAIN VIEW, Calif., Oct. 1 IRIDEX Corporation ... FlexFiber(TM) a laser fiber probe intended for effective delivery ... procedures. Introduced at the 2009 American Academy of ... , this consumable product represents an increase in IRIDEX, ...
Cached Medicine Technology:Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer 2IRIDEX Introduces New ENT Laser Delivery Devices at AAO-HNSF Annual Meeting 2
(Date:12/20/2014)... The holidays can be anything but joyous for people ... candles and other allergy triggers. "The dust from ... packed away in dank basements or dusty attics is ... Rachna Shah, an affiliate faculty member at Loyola University ... release. Shah, who is also an allergist at ...
(Date:12/20/2014)... 20, 2014 The Doctor’s Office Urgent Care ... better part of a decade. They’ve treated over 40,000 ... faster healthcare alternative to the Paramus area. ... new additions to their staff of top-notch board certified physicians: ... MD. These new doctors will work tirelessly to ...
(Date:12/20/2014)... New York (PRWEB) December 20, 2014 ... continue to move forward in U.S. courts, Bernstein ... study which suggests that children treated with the ... hormone linked to breast development and lactation. The ... at 34 children and adolescents who began treatment ...
(Date:12/20/2014)... 20, 2014 The aftermath of the November ... stir, not only in Hollywood, but worldwide. As ... the ripples of that attack are starting a finger-pointing game ... risk. But they are not the only ones affected, ... in for some embarrassing times ahead, agents and lawyers could ...
(Date:12/20/2014)... 2014 Developers of FCPX ... new plugin for Final Cut Pro X entitled TranSlice ... 5 allows users to create hand drawn text animations ... Austin, CEO of Pixel Film Studios. “TranSlice Volume 5 ... maintaining an easy to use interface.” , TranSlice Volume ...
Breaking Medicine News(10 mins):Health News:Holiday Trimmings Can Trigger Allergies 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2
... , , , NEW YORK, ... is available in its catalogue. , , ... http://www.reportlinker.com/p0131247/Lung-Cancer-Therapeutics.html , , ... Cancer Therapeutics in Millions of US$. The US market for Non-Small ...
... ... Diego, CA adds General Motors and Qualcomm to the program! , ... Portland, ME (PRWEB) September 8, 2009 -- Image Sensors ... San Diego, CA. The 3rd annual international event will address the latest trends and technologies ...
... , , , Will ... , , NEW YORK, Sept. 8 MARK ... of Lighthouse International, the 104-year-old non-profit leader in vision healthcare, research, ... in healthcare management, will start in his new role on September ...
... , ... head back to school , ... (PRWEB) September 8, 2009 -- As the unemployment rate in Canada holds steady at 8.6%, more ... the recession. , , , ,CDI College, a career college with 13 campus locations across Canada, ...
... The New York Football Giants are asking their fans to ... EAST RUTHERFORD, N.J., Sept. 8 We heard you bleed BLUE! ... ) , (Logo: http://www.newscom.com/cgi-bin/prnh/20090908/DC71650LOGO ) , , On ... with the American Red Cross to host a blood drive. The ...
... Sept. 8 Give an Hour(TM), a national nonprofit organization providing ... their loved ones, announces results of its August 2009 survey and ... survey in May 2009. , , Give an ... effectiveness and to determine how programs and services can be adapted ...
Cached Medicine News:Health News:Reportlinker Adds Lung Cancer Therapeutics Report 2Health News:Reportlinker Adds Lung Cancer Therapeutics Report 3Health News:Reportlinker Adds Lung Cancer Therapeutics Report 4Health News:Reportlinker Adds Lung Cancer Therapeutics Report 5Health News:Reportlinker Adds Lung Cancer Therapeutics Report 6Health News:Reportlinker Adds Lung Cancer Therapeutics Report 7Health News:Reportlinker Adds Lung Cancer Therapeutics Report 8Health News:Reportlinker Adds Lung Cancer Therapeutics Report 9Health News:Reportlinker Adds Lung Cancer Therapeutics Report 10Health News:Image Sensors 2009 Offers Promotional Discount on Machine Vision and Wireless Power Summits 2Health News:Image Sensors 2009 Offers Promotional Discount on Machine Vision and Wireless Power Summits 3Health News:Mark G. Ackermann Is Named New President and CEO of Lighthouse International 2Health News:Mark G. Ackermann Is Named New President and CEO of Lighthouse International 3Health News:Fall 2009 Sees Spike in Enrollments at CDI College 2Health News:New York Giants to Host American Red Cross Blood Drive 2Health News:Give an Hour(TM)'s Volunteer Mental Health Professionals Provide Nearly $1.7 Million in Services to Iraq and Afghanistan Veterans, Families, and Communities 2
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: